Chris Garabedian × Graig Suvannavejh × Sam Fazeli × Brian Skorney × Yaron Werber

Pharma buyers remain active in early-stage assets and China, though term sheets do not guarantee Q4 closings.Amvuttra sales fell to $81 million from $129 million in Q2 as Alnylam cut franchise guidance for a second time this year.AI may reduce data-gathering costs, but a 10,000-patient cardiovascular study still takes five years and $300 million.

Graig Suvannavejh × Paul Matteis × Brian Skorney × Yaron Werber × Jake Becraft

XBI remains up 20% YTD but fell from 169 to roughly 146 amid biotech’s largest cumulative hedge-fund de-grossing in more than five years.IPO markets remain open but favor clinical catalysts and defensible IP; M&A could restart buying, while Bristol’s low-dose-only significant admilparant result supports LPA1 in IPF but leaves dose response unresolved.

Peter Diamandis × Salim Ismail × Dave Blundin × Alexander Wissner-Gross

OpenAI’s October 6 release of 722 math solutions signals automation in verifiable research; cryptography’s absence drew Alex’s post-quantum risk warning.Meta’s active memory and 3.6 billion daily users offer reach, but Alex says Muse trails on cost.Alex forecasts the $1.8 billion virtual-cell initiative could yield cures for 5,000 diseases within two to three years, pending FDA acceptance.

Graig Suvannavejh × Sam Fazeli × Eric Schmidt × Brian Skorney

Biotech’s 27% XBI gain through September masks a punishing ownership unwind, as underowned and heavily shorted names offset specialist-fund selling.Regeneron-Sanofi’s $1 billion upfront and AstraZeneca’s $2 billion Summit investment show strategic capital is flowing, but HARMONi-3 remains a potentially historic binary event.China-origin deals and Lilly’s obesity data sharpen competition, while financing, durability, tolerability, and endpoint risk still dictate outcomes.

Sam Fazeli × Yaron Werber × Brian Skorney × Matt Gline

Biotech’s healthy headline tape masked long-short degrossing and rate sensitivity, while 22 IPOs and record-period average proceeds showed primary-market resilience.MFN may rebalance global contributions through revenue sharing rather than simply cut U.S. prices, but Europe could restrict access or favor cheaper Chinese drugs; meanwhile, durable VK2735 efficacy, Celldex safety and Vertex’s interim analysis define catalysts.

Josh Schimmer × Eric Schmidt × Paul Matteis × Adam Feuerstein

XBI fell roughly 4% month to date and 9%-10% from its highs, but remained up about 30% for the year, suggesting nervous consolidation rather than a broken thesis.Xenon’s nearly 30% selloff after pausing depression enrollment came despite no clinical hold and about 360 patients enrolled, showing how bounded safety data can become a franchise scare.Sionna’s failed add-on study reinforced Vertex’s cystic-fibrosis moat, while a switch study remains the key test.

Tess Cameron × Brian Skorney × Paul Matteis × Yaron Werber

HORIZON was “completely negative” despite pelacarsen reducing Lp(a) 80%, challenging biomarker shortcuts as Amgen fell 10% on read-through.Novartis’s Avidity failure less than a year after the $12 billion acquisition drove Artisan’s sales cut of about $5 billion and EPS CAGR to 4%.Dyne’s 25% placebo-adjusted CASI-22 splice correction and Roivant’s 56% PVR reduction set up catalysts, while endpoint and outcome risks remain.

Daphne Zohar × Eric Schmidt × Sam Fazeli × Graig Suvannavejh

Biotech’s 80% XBI rally is structurally M&A-led, with roughly $138B announced against $59B of equity issuance, compressing premiums and leaving no preclinical IPOs.Moderna’s melanoma vaccine suggests a durable trade-secret franchise, while BioNTech’s colorectal failure leaves tumor context unresolved; daraxonrasib’s $478K price and frontline label, and ivonescimab’s HARMONi-3 in 6–9 months, set the key monitoring points.

Yushan × 英博

Moderna8月19日单日上涨177%，市场重估焦点转向肿瘤疫苗的增长与定价空间。INTerpath-001试验显示，个性化疫苗联合Keytruda的无复发生存达统计学显著；但OS、HR及亚组数据未披露，商业化仍取决于4至6周生产与耗材成本。

Chris Garabedian × Graig Suvannavejh × Paul Matteis × Tess Cameron

Biotech’s tape is “healthy but discerning,” with 19 Nasdaq issues year-to-date and the XBI outperforming, yet market-neutral shorts have struggled as heavily shorted names such as Crinetics and Apogee were acquired.Tenex and Sionna failures show how sharply negative data is punished, while MindMed’s durable Phase 3 LSD effect and Belite’s February 12, 2027 PDUFA create catalysts amid continuing diligence and competitive risks.